Literature DB >> 18612769

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

Marco Capobianco1, Simona Malucchi, Stefano Ulisciani, Carmen Fava, Giovanna Rege Cambrin, Luigina Avonto, Giuseppe Saglio, Antonio Bertolotto.   

Abstract

Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was treated by polychemotherapy and autologous bone marrow transplantation with complete recovery of t-AML and stabilization of the neurological disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18612769     DOI： 10.1007/s10072-008-0934-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  21 in total

1.  Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.

Authors:  C Heesen; M Bruegmann; J Gbdamosi; E Koch; A Mönch; C Buhmann
Journal:  Mult Scler       Date:  2003-03       Impact factor: 6.312

2.  Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis.

Authors:  B Delisse; J de Seze; A Mackowiak; J B N'Kendjuo; A Verier; O Derepeer; C Boisselier; P Devos; P Hautecoeur; P Vermersch
Journal:  Mult Scler       Date:  2004-02       Impact factor: 6.312

3.  Therapy-related leukemia in mitozantrone treated patients.

Authors:  Donald E Goodkin
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312

4.  Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.

Authors:  A V Novoselac; S Reddy; J Sanmugarajah
Journal:  Leukemia       Date:  2004-09       Impact factor: 11.528

5.  Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

Authors:  D Brassat; C Recher; E Waubant; E Le Page; F Rigal-Huguet; G Laurent; G Edan; M Clanet
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

Review 6.  Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.

Authors:  Raymond Voltz; Michaela Starck; Vera Zingler; Michael Strupp; Hans-Jochem Kolb
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

7.  Therapy-related acute promyelocytic leukemia.

Authors:  M Beaumont; M Sanz; P M Carli; F Maloisel; X Thomas; L Detourmignies; A Guerci; N Gratecos; C Rayon; J San Miguel; J Odriozola; J Y Cahn; F Huguet; A Vekhof; A Stamatoulas; H Dombret; F Capote; J Esteve; A M Stoppa; P Fenaux
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

8.  [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].

Authors:  S Nollet; E Berger; E Deconinck; E Baldauf; L Rumbach
Journal:  Rev Neurol (Paris)       Date:  2006-02       Impact factor: 2.607

Review 9.  A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Authors:  R G Ghalie; E Mauch; G Edan; H P Hartung; R E Gonsette; S Eisenmann; E Le Page; M D Butine; D E De Goodkin
Journal:  Mult Scler       Date:  2002-10       Impact factor: 6.312

Review 10.  Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.

Authors:  M J Ratain; J D Rowley
Journal:  Ann Oncol       Date:  1992-02       Impact factor: 32.976
View more
  2 in total

1.  Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

Authors:  Kaitlyn Koenig Thompson; Stella E Tsirka
Journal:  Handb Exp Pharmacol       Date:  2022

2.  Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Authors:  Enrico C Lallana; Camilo E Fadul
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.